Bradley R. Corr, MD, explores the rationale and results of a phase 2 trial comparing rucaparib to placebo as maintenance therapy for metastatic and recurrent endometrial cancer. Discover the significant progression-free survival improvements and implications for patients in this insightful discussion.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045